Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646721 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
A Phase 1 study, sponsored by Dong-A ST Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
NCT03646721 is a Phase 1 study that has completed, run by Dong-A ST Co.. The registered enrollment target is 108 participants.
The verdict
NCT03646721, a Phase 1 study, has completed, sponsored by Dong-A ST Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG DA-1241
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03646721
The ClinicalTrials.gov registry entry for NCT03646721 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dong-A ST Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03646721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03646721 about?
NCT03646721 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM". This is a double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, PK and PD of DA-1241 in healthy male subjects and subjects with T2DM
What is the current status of trial NCT03646721?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2018-08-29. Estimated completion is 2020-05-07.
What interventions are being tested in trial NCT03646721?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), DA-1241 (DRUG).
Who is sponsoring clinical trial NCT03646721?
This trial is sponsored by Dong-A ST Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.